News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
Vernalis PLC Says “Striking” Results for Obesity Drug
September 13, 2007
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
LONDON, Sept 13 (Reuters) - Britain's Vernalis (VER.L: Quote, Profile, Research) said on Thursday its V24343 treatment for obesity had helped patients achieve "striking weight loss" in an early stage clinical study.
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Phase I
Europe
MORE ON THIS TOPIC
Podcast
Shutdown Pauses New Drug Reviews, CDC Issues New COVID Guidance, CGT Meets on Mesa
October 8, 2025
·
1 min read
·
Heather McKenzie
Obesity
Skye’s CB1 Inhibitor Shows ‘Intriguing Synergy’ With Wegovy, Despite Mid-Stage Obesity Fail
October 7, 2025
·
2 min read
·
Tristan Manalac
Opinion
Gene Therapy’s Future Hinges on the Economics of Safety
October 6, 2025
·
7 min read
·
Ronald A. Li
Multiple sclerosis
Beyond BTK Inhibitors: Next Gen MS Treatments Could Transcend Symptom Management
October 6, 2025
·
5 min read
·
Ben Hargreaves
